Skip to main content
Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.300
+0.090 (2.14%)
At close: Nov 13, 2026, 4:00 PM EST
4.360
+0.060 (1.40%)
After-hours: Nov 13, 2026, 7:25 PM EST

Atea Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-----351.37
Revenue Growth
-----622.49%
Cost of Revenue
143.97146.5383.3770.6162.39167.21
Gross Profit
-143.97-146.53-83.37-70.61-62.39184.16
Selling, General & Admin
27.8632.8648.8549.9248.7145.79
Operating Expenses
27.8632.8648.8549.9248.7145.79
Operating Income
-171.83-179.4-132.22-120.53-111.1138.38
Interest & Investment Income
1016.3825.4929.2211.150.21
EBT Excluding Unusual Items
-161.84-163.02-106.73-91.31-99.95138.59
Other Unusual Items
-0.22-1.49-60.73-43.63-19.55-
Pretax Income
-162.06-164.51-167.46-134.94-119.5138.59
Income Tax Expense
-6.66-6.160.931.02-3.5917.4
Net Income
-155.4-158.35-168.39-135.96-115.91121.19
Net Income to Common
-155.4-158.35-168.39-135.96-115.91121.19
Net Income Growth
------
Shares Outstanding (Basic)
798184838383
Shares Outstanding (Diluted)
798184838388
Shares Change
-4.44%-3.29%1.05%0.17%-5.67%308.70%
EPS (Basic)
-1.96-1.94-2.00-1.63-1.391.46
EPS (Diluted)
-1.96-1.94-2.00-1.63-1.391.37
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-140.57-132.03-135.5-85.4-122.93-87.01
Free Cash Flow Per Share
-1.77-1.62-1.61-1.02-1.48-0.99
Gross Margin
-----52.41%
Operating Margin
-----39.38%
Profit Margin
-----34.49%
Free Cash Flow Margin
------24.76%
EBITDA
-171.42-178.98-131.8-120.11-110.84138.41
EBITDA Margin
-----39.39%
D&A For EBITDA
0.420.420.420.420.260.03
EBIT
-171.83-179.4-132.22-120.53-111.1138.38
EBIT Margin
-----39.38%
Effective Tax Rate
-----12.55%
SEC Filings: 10-K · 10-Q